Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
1999 1
2000 2
2002 3
2003 1
2004 2
2005 3
2006 3
2007 3
2008 1
2009 7
2010 3
2011 8
2012 9
2013 7
2014 14
2015 10
2016 17
2017 20
2018 15
2019 13
2020 27
2021 16
Text availability
Article attribute
Article type
Publication date

Search Results

166 results
Results by year
Filters applied: . Clear all
Page 1
Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer.
Ruscetti M, Morris JP 4th, Mezzadra R, Russell J, Leibold J, Romesser PB, Simon J, Kulick A, Ho YJ, Fennell M, Li J, Norgard RJ, Wilkinson JE, Alonso-Curbelo D, Sridharan R, Heller DA, de Stanchina E, Stanger BZ, Sherr CJ, Lowe SW. Ruscetti M, et al. Among authors: de stanchina e. Cell. 2020 Apr 16;181(2):424-441.e21. doi: 10.1016/j.cell.2020.03.008. Epub 2020 Mar 31. Cell. 2020. PMID: 32234521 Free PMC article.
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.
Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, Lee E, Barnes SD, Chen HA, Mao N, Wongvipat J, Choi D, Chen X, Zhao H, Manova-Todorova K, de Stanchina E, Taplin ME, Balk SP, Rathkopf DE, Gopalan A, Carver BS, Mu P, Jiang X, Watson PA, Sawyers CL. Zhang Z, et al. Among authors: de stanchina e. Cancer Cell. 2020 Aug 10;38(2):279-296.e9. doi: 10.1016/j.ccell.2020.06.005. Epub 2020 Jul 16. Cancer Cell. 2020. PMID: 32679108 Free PMC article.
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, Arena S, Montone M, Mussolin B, Bian Y, Whaley A, Pinnelli M, Murciano-Goroff YR, Vakiani E, Valeri N, Liao WL, Bhalkikar A, Thyparambil S, Zhao HY, de Stanchina E, Marsoni S, Siena S, Bertotti A, Trusolino L, Li BT, Rosen N, Di Nicolantonio F, Bardelli A, Misale S. Amodio V, et al. Among authors: de stanchina e. Cancer Discov. 2020 Aug;10(8):1129-1139. doi: 10.1158/2159-8290.CD-20-0187. Epub 2020 May 19. Cancer Discov. 2020. PMID: 32430388 Free PMC article.
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition.
Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, Kim D, Li C, de Stanchina E, Mazutis L, Risso D, Lito P. Xue JY, et al. Among authors: de stanchina e. Nature. 2020 Jan;577(7790):421-425. doi: 10.1038/s41586-019-1884-x. Epub 2020 Jan 8. Nature. 2020. PMID: 31915379 Free PMC article.
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, Taylor BS, Rosen N. Yao Z, et al. Among authors: de stanchina e. Nature. 2017 Aug 10;548(7666):234-238. doi: 10.1038/nature23291. Epub 2017 Aug 2. Nature. 2017. PMID: 28783719 Free PMC article.
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.
Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, Chen CC, Ho YJ, Sanchez-Rivera FJ, Feucht J, Baslan T, Tian S, Chen HA, Romesser PB, Poirier JT, Rudin CM, de Stanchina E, Manchado E, Sherr CJ, Lowe SW. Ruscetti M, et al. Among authors: de stanchina e. Science. 2018 Dec 21;362(6421):1416-1422. doi: 10.1126/science.aas9090. Science. 2018. PMID: 30573629 Free PMC article.
p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression.
Moon SH, Huang CH, Houlihan SL, Regunath K, Freed-Pastor WA, Morris JP 4th, Tschaharganeh DF, Kastenhuber ER, Barsotti AM, Culp-Hill R, Xue W, Ho YJ, Baslan T, Li X, Mayle A, de Stanchina E, Zender L, Tong DR, D'Alessandro A, Lowe SW, Prives C. Moon SH, et al. Among authors: de stanchina e. Cell. 2019 Jan 24;176(3):564-580.e19. doi: 10.1016/j.cell.2018.11.011. Epub 2018 Dec 20. Cell. 2019. PMID: 30580964 Free PMC article.
The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase.
Sanghvi VR, Leibold J, Mina M, Mohan P, Berishaj M, Li Z, Miele MM, Lailler N, Zhao C, de Stanchina E, Viale A, Akkari L, Lowe SW, Ciriello G, Hendrickson RC, Wendel HG. Sanghvi VR, et al. Among authors: de stanchina e. Cell. 2019 Aug 8;178(4):807-819.e21. doi: 10.1016/j.cell.2019.07.031. Cell. 2019. PMID: 31398338 Free PMC article.
DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia.
Johnson DC, Taabazuing CY, Okondo MC, Chui AJ, Rao SD, Brown FC, Reed C, Peguero E, de Stanchina E, Kentsis A, Bachovchin DA. Johnson DC, et al. Among authors: de stanchina e. Nat Med. 2018 Aug;24(8):1151-1156. doi: 10.1038/s41591-018-0082-y. Epub 2018 Jul 2. Nat Med. 2018. PMID: 29967349 Free PMC article.
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.
Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, Huang CH, de Stanchina E, Lowe SW, Ellis L, Beltran H, Rubin MA, Goodrich DW, Demichelis F, Sawyers CL. Mu P, et al. Among authors: de stanchina e. Science. 2017 Jan 6;355(6320):84-88. doi: 10.1126/science.aah4307. Science. 2017. PMID: 28059768 Free PMC article.
166 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page